Tuesday, April 14, 2015

Top 10 Medical Stocks To Own For 2015

Top 10 Medical Stocks To Own For 2015: Johnson & Johnson(JNJ)

Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment provides products used in baby care, skin care, oral care, wound care, and women?s health care fields, as well as nutritional, over-the-counter pharmaceutical products, and wellness and prevention platforms under the brands of JOHNSON?S, AVEENO, CLEAN & CLEAR, JOHNSON?S Adult, NEUTROGENA, RoC, LUBRIDERM, DABAO, LISTERINE, REACH, BAND-AID, CAREFREE, STAYFREE, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID AC. The Pharmaceutical segment offers products in various therapeutic areas, such as anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, and virology. Its principal products include REMICADE for the treatment of immune me diated inflammatory diseases; STELARA for the treatment of moderate to severe plaque psoriasis; SIMPONI, a treatment for adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; VELCADE for the treatment of multiple myeloma; PREZISTA and INTELENCE for treating HIV/AIDS patients; NUCYNTA for moderate to severe acute pain; INVEGA SUSTENNAtm for the acute and maintenance treatment of schizophrenia in adults; RISPERDAL CONSTA for the management of bipolar I disorder and schizophrenia; and PROCRIT to stimulate red blood cell production. The Medical Devices and Diagnostics segment primarily offers circulatory disease management products; orthopaedic joint reconstruction, spinal care, and sports medicine products; surgical care, aesthetics, and women?s health products; blood glucose monitoring and insulin delivery products; professiona! l diagnostic products; and disposable contact lenses. The company was founded in 1886 and is based in N e w Brunswick, New Jersey.

Advisors' Opinion:
  • [By Brian Orelli]

    On Monday, Gilead Sciences announced an expanded agreement with Johnson & Johnson (NYSE: JNJ  ) to develop two different of cocktail pills to treat HIV. One drug will combine Gilead's tenofovir alafenamide, commonly called TAF, and Emtriva with Johnson & Johnson's Edurant. The other combines Gilead's TAF, Emtriva, and Tybost, along with Janssen's Prezista.

  • [By John Udovich]

    Small cap biopharmaceutical stock Vanda Pharmaceuticals Inc (NASDAQ: VNDA) surged 14.02% after announcing a settlement agreement with Novartis AG (NYSE: NVS) related to ongoing license arbitration proceedings for Fanapt, a schizophrenia treatment drug – meaning its worth taking a closer look at the stock along with large caps Johnson & Johnson (NYSE: JNJ) and Bristol-Myers Squibb Co (NYSE: BMY) which also have important schizophrenia drugs in their portfolios.

  • [By Motley Fool Staff]

    Todd Campbell: In my view, the most disappointing trial failure this year has got to be Exelixis' (NASDAQ: EXEL  ) study of cabozantinib in prostate cancer patients. Investors had high hopes for cabozantinib given that competing prostate cancer treatments developed by Johnson & Johnson  (NYSE: JNJ  ) and Medivation  (NASDAQ: MDVN  ) had gone on to achieve billion dollar sales run rates following their approval.

  • [By Ben Levisohn]

    Stocks with low turnover include Philip Morris International (PM), Schlumberger (SLB), Johnson & Johnson (JNJ), General Electric (GE) and Automatic Data Processing (ADP).

  • source from Top Stocks For 2015:http://www.topstocksblog.com/top-10-medical-stocks-to-own-for-2015-2.html

No comments:

Post a Comment